The Gut Healing Stack: BPC-157, KPV & LL-37 for Digestive Health
A physician's guide to the gut healing peptide stack. How BPC-157, KPV, and LL-37 work together to repair, calm, and rebalance your digestive system.
Why Gut Health Matters
The gastrointestinal tract is far more than a food processing tube. It houses approximately 70% of your immune system, produces the majority of your serotonin, and maintains a complex ecosystem of trillions of microorganisms that influence everything from metabolism to mood. When gut function breaks down, the effects ripple through the entire body.
Intestinal permeability, often called leaky gut, occurs when the tight junctions between gut lining cells become compromised. This allows partially digested food particles, bacteria, and toxins to pass through the gut wall into the bloodstream, triggering immune activation and systemic inflammation. Chronic gut dysfunction has been linked to autoimmune conditions, skin problems, brain fog, mood disorders, and metabolic issues.
Standard approaches to gut health, including dietary changes, probiotics, and anti-inflammatory supplements, help many patients. But for those with persistent gut dysfunction that has not responded adequately to these interventions, targeted peptide therapy offers a more direct approach to healing the gut lining itself.
The Three Peptides in This Stack
BPC-157: The Gut Healer
BPC-157 is perhaps the most naturally suited peptide for gut applications. It is derived from a protein found in human gastric juice, literally a product of the digestive system itself. Unlike most peptides that are degraded by stomach acid, BPC-157 is remarkably stable in the GI tract, which is why it can be taken orally for gut-specific targeting.
Research has demonstrated that BPC-157 promotes healing of the gut mucosal lining through angiogenesis (new blood vessel formation) and growth factor upregulation. It has shown protective effects against NSAID-induced stomach damage, alcohol-induced gastric lesions, and various experimental models of inflammatory bowel conditions. For patients who have been on long-term NSAID therapy and are dealing with the gut consequences, BPC-157 is often the first peptide considered.
BPC-157 is the foundation peptide of the Wolverine Stack (with TB-500), the Glow Stack (adding GHK-Cu), and the KLOW Stack (adding both GHK-Cu and KPV). In the gut healing context, it serves as the primary tissue repair agent.
KPV: The Anti-Inflammatory
KPV is a tripeptide (just three amino acids: lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Despite its tiny size, KPV has potent anti-inflammatory properties that work through a specific and well-characterized mechanism: it inhibits NF-kB, one of the master regulatory switches controlling inflammatory gene expression throughout the body.
What makes KPV particularly interesting for gut applications is that it calms inflammation without broadly suppressing the immune system. This is a critical distinction from drugs like corticosteroids, which reduce inflammation at the cost of immune function. KPV modulates the inflammatory response, dialing it down where excessive while preserving normal immune surveillance.
Research in models of inflammatory bowel disease has shown that oral KPV reduced colonic inflammation and promoted mucosal healing. Its small size also means it can be absorbed orally, making it practical for gut-targeted therapy.
LL-37: The Antimicrobial
LL-37 is a human cathelicidin antimicrobial peptide, part of your innate immune system's first line of defense. It has broad-spectrum activity against bacteria, fungi, and some enveloped viruses. But calling it just an antimicrobial undersells its capabilities.
LL-37 also modulates immune responses, promotes wound healing in mucosal tissue, and helps maintain the balance of gut flora. For patients with dysbiosis (an imbalance in gut microbial populations), LL-37 can help rebalance the ecosystem by selectively targeting pathogenic organisms while being less disruptive to beneficial bacteria than conventional antibiotics.
Unlike BPC-157 and KPV, LL-37 is not stable when taken orally and is typically administered via subcutaneous injection.
How the Stack Works Together
The gut healing stack operates on a clear logic: address the microbial imbalance, calm the inflammation, and rebuild the tissue. LL-37 tackles dysbiosis and helps clear pathogenic organisms that may be contributing to ongoing gut dysfunction. KPV dials down the inflammatory cascade that is damaging the gut lining and preventing healing. BPC-157 directly promotes repair and regeneration of the mucosal tissue itself.
This sequential healing approach, clear infection, reduce inflammation, rebuild tissue, mirrors how the body naturally recovers from gut injury, but accelerates each phase through targeted peptide support.
Who May Benefit
The gut healing stack may be worth discussing with your provider if you are dealing with chronic IBS or digestive dysfunction that has not fully resolved with dietary changes, post-antibiotic gut recovery where the microbiome has been disrupted, NSAID-related gut damage from long-term use of medications like ibuprofen or naproxen, persistent food sensitivities that suggest underlying intestinal permeability, chronic bloating, irregular bowel patterns, or abdominal discomfort, or inflammatory bowel conditions under physician supervision.
This stack is not a replacement for proper diagnostic workup. Persistent gut symptoms should be evaluated by a gastroenterologist to rule out serious conditions before starting peptide therapy.
Dosage Protocol
A typical gut healing protocol starts with BPC-157 at 500 mcg per day taken orally for gut-specific targeting. Oral administration is preferred here because it delivers the peptide directly to the GI tract where it is needed most. Some providers use 250 mcg subcutaneously as an alternative or in addition to oral dosing.
KPV is administered at 200 to 500 mcg per day, either orally or subcutaneously. Oral KPV has the advantage of direct gut exposure, though subcutaneous administration provides systemic anti-inflammatory benefits as well.
LL-37 is given at 50 to 100 mcg per day via subcutaneous injection. It cannot be taken orally because it would be degraded by digestive enzymes before reaching its target.
A typical cycle runs 8 to 12 weeks. Some providers recommend starting with BPC-157 alone for the first 2 weeks to establish tissue repair, then adding KPV and LL-37 based on the patient's specific presentation and response.
What to Expect: Timeline
- Week 1 to 2: Reduced bloating and general GI discomfort. Many patients report that the most acute symptoms begin to ease during this initial phase.
- Week 3 to 4: Improved digestion and more regular bowel patterns. Food sensitivities may begin to lessen as gut permeability starts to improve.
- Week 6 to 8: Significant symptom improvement. Patients often report meaningful reductions in IBS-type symptoms and improved tolerance for foods that previously caused issues.
- Week 8 to 12: Continued mucosal healing and stabilization of gut function. Benefits often persist beyond the end of the treatment cycle as the repaired tissue maintains its integrity.
Safety
All three peptides in this stack have favorable safety profiles based on available research. BPC-157 has the most extensive data and is generally well tolerated with minimal side effects. KPV is considered safe based on the limited human data available, with no significant adverse effects reported. LL-37 may occasionally cause injection site reactions.
Contraindications include active cancer, pregnancy, and breastfeeding. Patients with active infections should have those addressed before or alongside peptide therapy, in coordination with their healthcare provider.
Working with a provider who has specific experience with gut-focused peptide protocols is particularly important for this stack, as dosing and sequencing decisions benefit from clinical experience.
Complementary Approaches
Peptide therapy for gut health works best as part of a comprehensive approach. An elimination diet or anti-inflammatory dietary protocol can reduce the ongoing insults to the gut lining while peptides promote repair. Targeted probiotics and prebiotics support the reestablishment of healthy gut flora alongside LL-37's microbial rebalancing effects.
Stress management deserves special mention. The gut-brain axis is a bidirectional communication system, meaning chronic stress directly impairs gut function and slows healing. Incorporating stress reduction practices like meditation, adequate sleep, and regular exercise meaningfully supports the peptide healing process.
Finally, peptide therapy does not replace appropriate medical evaluation and management of underlying conditions. A proper diagnostic workup, including endoscopy or colonoscopy when indicated, should precede or accompany any peptide gut healing protocol.